Navigation Links
Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
Date:2/23/2011

of ARIDOL as a bronchial challenge test were verified in two global Phase III clinical trials, which assessed the effectiveness of the ARIDOL bronchial challenge test in non-asthmatic patients with symptoms suggestive of asthma and clinically diagnosed asthmatic patients six years of age and older.  Approved for use in 19 countries, ARIDOL has been used by more than 44,000 patients, and is marketed in Australia, major European countries and Korea.  ARIDOL is included in official international guidelines for the clinical assessment of asthma. Organizations and guidelines endorsing ARIDOL include: the International Olympic Committee Medical Commission's Independent Panel on Asthma, the U.S. Asthma Management Guidelines, the Global Initiative for Asthma (GINA) Report on Global Strategy for Asthma Management and Prevention, the World Anti-Doping Agency and the Australian Asthma Management Handbook. ARIDOL is the only dry powder bronchial challenge test approved for use in the U.S.

Indication

Mannitol, the active ingredient in ARIDOL, is a sugar alcohol indicated for the assessment of bronchial hyperresponsiveness in patients 6 years of age or older who do not have clinically apparent asthma.  

ARIDOL is not a stand alone test or a screening test for asthma.  Bronchial challenge testing with ARIDOL should be used only as part of a physician's overall assessment of asthma.

Important Safety Information

WARNING: RISK OF SEVERE BRONCHOSPASM

Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm.  Bronchial challenge testing with ARIDOL is for diagnostic purposes only.  Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short acting inh
'/>"/>

SOURCE Pharmaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
2. Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
3. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
4. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
5. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
6. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
7. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
8. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
9. Pharmaxis Establishes Named Patient Program for Bronchitol
10. Pharmaxis Long-Term Safety Study of Bronchitol Completes
11. Healthpoint Launches New Corporate Identity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... July 30, 2015 Flexpoint Ford, a private ... sectors, today announced that it has entered into a ... Stuart to form Kastle Therapeutics, LLC (Kastle).  The ... will focus on acquiring, developing and commercializing pharmaceuticals targeted ... opportunities include select therapies already approved for marketing, as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... Science is largely a collaborative enterprise. Frequently researchers ... pool their efforts and exchange ideas, to devise ... such as those known as autism spectrum disorders, ... on diverse populations of patients, finding a broader ...
... Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease ... Blinded one-year blood pressure (BP) reduction data from the ongoing ... lmesartan A nd D iabetes M icro ... American Society of Hypertension (ASH) Twenty-Fourth Annual Scientific Meeting and ...
Cached Medicine Technology:Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 2Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 3Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 4Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 5Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 6Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 7
(Date:7/30/2015)... (PRWEB) , ... July 30, ... ... released a video, “Beachside Nursing Center,” to announce its position as one ... ratings. Beachside's administrator and staff members support the CMS rating system, which ...
(Date:7/30/2015)... Plainsboro, NJ (PRWEB) , ... July 30, 2015 ... ... partners continues to expand, as the company and UCLA’s Jonsson Comprehensive Cancer ... research, OncLive announced today. With the new collaboration, OncLive’s editorial and marketing groups ...
(Date:7/30/2015)... ... 30, 2015 , ... The Mesothelioma Applied Research Foundation (Meso ... Act of 2015’. The bill was introduced in Congress yesterday by Representatives John ... (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students and ... Games, the largest sports and humanitarian event in the world this year and the ... Games, held July 25 through August 2, 2015, benefited from the participation of WesternU’s ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Between 2012 ... to the Health News Florida on June 17th. Those untreated heroin use ... programs to prevent the spread of dirty needles throughout the community. Ultimately Florida’s HIV ...
Breaking Medicine News(10 mins):Health News:Beachside Nursing Center Releases New Video 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... Child Deserves The Opportunity To Smile.PACIFIC PALISADES, Calif., April ... every child,s life is the opportunity to smile. BrittiCares ... just that. BrittiCares (BCI) will hold its 4th annual ... Pacific Palisades High School. Hosted by Chris Tucker, the ...
... Alliance Announces Eight New Associate Members to Help Raise ... Eight medical groups, public health associations and obesity ... O vercome and P revent (STOP) Obesity ... and private sector decision makers grappling with the high ...
... Elsevier, the world-leading publisher of scientific, technical ... to announce the launch of a new journal, ... infectious disease dynamics ( http://www.elsevier.com/locate/epidemics ). , ... disease dynamics in the broadest sense. Its scope ...
... Gold Standard Status for Bipolar Depression, According to ... 27 Decision Resources, one of the world,s ... healthcare issues, finds that surveyed psychiatrists identify a ... symptoms as the attribute that most influences their ...
... Senior Living, Inc. (OTC Bulletin Board: TCSR), which develops, ... the expansion of its presence on radio in coordination ... talk radio program heard daily on over 265 radio ... a large and growing national audience, and we are ...
... is largely underpenetrated, according to Millennium Research GroupWALTHAM, ... Group,s (MRG,s) Opportunities in Brazil ... Market 2009 report, Brazil is extremely underpenetrated ... devices. The varicose vein treatment device market in ...
Cached Medicine News:Health News:BrittiCares International 'Smile For Life' 5K Run/Walk Gears Up to Save Lives 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 3Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 4Health News:Elsevier launches Epidemics -- the journal on infectious disease dynamics 2Health News:For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms 2Health News:For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms 3Health News:National Radio Program to Expand Awareness of TrinityCare's Unique Approach to Senior Adult Care 2Health News:National Radio Program to Expand Awareness of TrinityCare's Unique Approach to Senior Adult Care 3Health News:Growth Opportunity in Brazil's Varicose Vein Treatment Device Market 2Health News:Growth Opportunity in Brazil's Varicose Vein Treatment Device Market 3
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: